News
Entertainment
Science & Technology
Life
Culture & Art
Hobbies
News
Entertainment
Science & Technology
Culture & Art
Hobbies
Discover Latest #Forex News, Articles and Videos with Contenting
Forex news is one of the most important factors in the Forex markets. This is why it is essential for traders to stay up to date on the latest news and developments. There are many sources of Forex news, including online sources, newspapers, magazines, and television. Here are some of the most popular sources for Forex news: 1. Online Forex News Sources: There are many websites that provide up to date Forex news. Some of the most popular sites include ForexLive, Forex Factory, and Forex Daily. These websites offer a range of news and analysis on the Forex markets, as well as a range of tools and resources to help traders make better decisions. 2. Newspapers: Newspapers are another great source of Forex news. Many newspapers have dedicated sections that cover the Forex markets and other financial markets. 3. Magazines: There are also a number of magazines that provide Forex news and analysis. Some of the most well-known magazines include Bloomberg, Wall Street Journal, and Financial Times. 4. Television: Television is also a great source of Forex news. Many news channels such as CNBC, Fox Business, and Bloomberg TV offer regular updates on the Fore
Italfarmaco Presents New Cardiac Data for Givinostat at 16th European Paediatric Neurology Society (EPNS) Congress - ForexTV
In total, 11 abstracts on givinostat were accepted for presentation at the Congress, including two for an oral presentation MILAN, Italy, July 11, 2025 – Italfarmaco S.p.A. announced today that new cardiac data for givinostat, a novel histone deacetylase (HDAC) inhibitor, in ambulant boys with Duchenne muscular dystrophy (DMD) will be presented at the European Paediatric Neurology Society (EPNS) Congress, taking place July 8 - 12, 2025 in Munich, Germany. Post hoc analysis from the completed Phase 3 EPIDYS trial showed less decline in cardiac function throughout the study, compared to those who received placebo. In addition, the analysis showed no prolongation of the QTc interval in either the placebo or givinostat treatment groups. In a separate crossover study conducted by Italfarmaco in healthy volunteers to assess the impact of a therapeutic and supratherapeutic dose of givinostat, the administration of the therapeutic dose was not associated with any risk of QTc interval prolongation. “Individuals with Duchenne are at risk of cardiac complications as the disease progresses. The beneficial trend observed with givinostat in preserving heart function compared to placebo is encouraging,” stated Paolo Bettica, MD, PhD, Chief Medical Officer at Italfarmaco Group. “Furthermore, these data support the cardiac safety profile of givinostat, providing additional confidence for its use. We are pleased to share these findings at the EPNS Congress.” Individuals with DMD experience progressive skeletal muscle degeneration, and over time, they are also at risk of developing impaired cardiac function. Reduced mobility and the underlying genetic defect contribute to an increased risk of cardiomyopathy and arrhythmias, making routine cardiac monitoring a critical component of clinical care and disease management. In the EPIDYS study, 179 ambulatory boys aged 6 years and older with genetically confirmed DMD were assessed throughout the 72-week trial on electrocardiogram (ECG) and echocardiogram (ECHO) parameters. At the end of the study, the givinostat-treated group showed a beneficial trend compared to the placebo group. In a separate Phase 1 crossover study, Italfarmaco evaluated the cardiac safety profile of a therapeutic and supratherapeutic dose of givinostat in healthy volunteers. The data demonstrated that the therapeutic dose of givinostat is not expected to pose a risk of QTc prolongation. The therapeutic dose of givinostat had no clinically relevant effect on heart rate or cardiac conduction, nor did it have a clinically relevant effect on the QTc interval. A total of 11 abstracts related to givinostat were accepted for either oral or poster presentation at the EPNS Congress. The list of all abstracts accepted for presentations can be accessed on the EPNS website using the search term “givinostat.” The European Commission (EC) granted givinostat (Duvyzat®) conditional marketing authorisation in the EU in June 2025 to ambulant DMD patients 6 years and older. Givinostat was also granted approval by the US Food and Drug Administration (FDA) in March 2024 for the treatment of DMD patients 6 years and older. In December 2024, the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) approved givinostat for patients 6 years and older who are ambulatory and granted conditional marketing approval for non-ambulatory patients. About Duchenne Muscular Dystrophy Duchenne muscular dystrophy (DMD) is a rare, progressive neuromuscular disorder caused by mutations in the DMD gene. Mutations in the DMD gene prevent the production of functional dystrophin, causing the dystrophin-associated protein complex (DAPC) to break down. This makes muscle fibres more vulnerable to damage and increases histone deacetylase (HDAC) levels in the muscle cells, blocking the activation of important genes needed for muscle maintenance and repair. As a result, muscle fibres experience ongoing damage, leading to chronic inflammation and poor regeneration. Over time, muscle cells die and are replaced by scar tissue and fat.1-4 DMD primarily affects males, with symptoms typically appearing between the ages of two and five. As the condition progresses, muscle weakness worsens, leading to difficulty walking and eventually to loss of ambulation. Over time, the heart and respiratory muscles are also affected, which are the leading causes of premature death.5 DMD is one of the most severe and common forms of childhood muscular dystrophy, with a global birth incidence of approximately 1 in 5,050 boys.6 About ITALFARMACO Founded in 1938 in Milan, Italy, Italfarmaco is a private global pharmaceutical company that has led the successful development and approval of many pharmaceutical products around the world. The Italfarmaco group has operations in more than 90 countries through directly controlled or affiliated companies. The company is a leader in pharmaceutical research, product development, production and commercialisation with proven success in many therapeutic areas including immuno-oncology, gynaecology, neurology, cardiovascular disease and rare diseases. Italfarmaco's rare disease unit includes programmes in Duchenne muscular dystrophy, Becker muscular dystrophy, amyotrophic lateral sclerosis and polycythaemia vera. Media enquiries:Anja Heuer / Adolfo Luna | +49 (0) 151 106 199 05 | italfarmaco@trophic.eu Other enquiries:Samantha Parker | Patient Advocacy and Communications Lead | RDEnquiries@italfarmacogroup.com References: Sandonà M, Cavioli G, Renzini A, et al. Histone Deacetylases: Molecular Mechanisms and Therapeutic Implications for Muscular Dystrophies. Int J Mol Sci. 2023;24(5):4306. https://doi.org/10.3390/ijms24054306.Consalvi S, Saccone V, Giordani L, Minetti G, Mozzetta C, Puri PL. Histone Deacetylase Inhibitors in the Treatment of Muscular Dystrophies: Epigenetic Drugs for Genetic Diseases. Mol Med. 2011;17(5):457–465. https://doi.org/10.2119/molmed.2011.00049.Bez Batti Angulski A, Hosny N, Cohen H, et al. Duchenne muscular dystrophy: disease mechanism and therapeutic strategies. Front Physiol. 2023;14:1183101. https://doi.org/10.3389/fphys.2023.1183101.Giuliani G, Rosina M, Reggio A. Signaling pathways regulating the fate of fibro/adipogenic progenitors (FAPs) in skeletal muscle regeneration and disease. FEBS J. 2022;289(21):6484–6517. https://doi.org/10.1111/febs.16080.Walter MC, Reilich P. Recent developments in Duchenne muscular dystrophy: facts and numbers. J Cachexia Sarcopenia Muscle. 2017;8(5):681–685. https://doi.org/10.1002/jcsm.12245.Crisafulli S, Sultana J, Fontana A, Salvo F, Messina S, Trifirò G. Global epidemiology of Duchenne muscular dystrophy: an updated systematic review and meta-analysis. Orphanet J Rare Dis. 2020;15(1):141. https://doi.org/10.1186/s13023-020-01430-8. Attachment Italfarmaco Presents New Cardiac Data for Givinostat at EPNS Congress
Hepsor Latvia OÜ, a subsidiary of Hepsor AS, acquires Latvian company Starta 17 SIA - ForexTV
Hepsor Latvia OÜ, a subsidiary of Hepsor AS, acquires a 100% holding in the Latvian company Starta 17 SIA (registry code 40203117159). Starta 17 SIA owns a property at Starta iela 17 in Riga. Three 14-storey apartment buildings with a total of 250 apartments and a net area of 14,500 m2 are planned to be built on the site. Phased construction is scheduled to start at the end of 2026. The total transaction price is EUR 1.25 million. For the realisation of the transaction, EUR 800,000 will be raised from partners, who will acquire a minority holding of 20% in Starta 17 SIA. The total investment in the development project is close to EUR 40 million, making it Hepsor’s largest development in the Latvian real estate market. According to Martti Krass, the Country Manager at Hepsor Latvia: ‘With our investment in Starta 17, we reaffirm our belief in the strength of the Riga real estate market – primary market real estate transaction activity in Riga has increased by more than 25% year-on-year and we expect the positive trend to continue. The homes to be built as part of the planned development will be located in Teika – an area that has seen a boom in new residential and commercial buildings in recent years. This has created strong demand for new housing, making Teika one of Riga’s most attractive areas for new developments.’ Hepsor has developed around 400 apartments in Latvia, 95% of which have been sold. A further 514 apartments will be completed in the coming years. Henri LaksMember of the Management BoardPhone: +372 5693 9114Email: henri@hepsor.ee Hepsor AS (www.hepsor.ee) is a developer of residential and commercial real estate. The Group operates in Estonia, Latvia and Canada. In fourteen years of operation, we have created 2 076 homes and nearly 36 300 m2 of commercial space. Hepsor is the first developer in the Baltic States to implement a number of innovative engineering solutions that will make the buildings it builds more energy efficient and thus more environmentally friendly. The company has a portfolio of 25 development projects with a total area of 172 800 m2.
Nikkei Ends Lower as Fast Retailing Slumps - ForexTV
On Friday, Japan's Nikkei 225 Index fell by 0.19%, closing at 39,569, as initial gains were reversed due to a significant sell-off in Fast Retailing shares, which negatively affected the overall market. Fast Retailing, the parent company of Uniqlo, saw its shares plunge by 6.9% following a warning that newly announced US tariffs would have a substantial impact on its US operations later in the year. This prompted the company to announce planned price increases. The cautionary statement came shortly after US President Donald Trump revealed a 25% tariff on Japanese products, effective August 1, intensifying the trade tensions between the US and Japan. In reaction, Prime Minister Shigeru Ishiba emphasized Japan's need to lessen its reliance on the US in key sectors such as defense, food security, and energy, describing the ongoing negotiations as a critical "battle" for national interest. Other prominent stocks that declined included Fujikura, which dropped 3.2%, Mitsubishi Heavy Industries, down 2.0%, and SoftBank Group, which fell by 1.4%.The material has been provided by InstaForex Company - www.instaforex.com
Solargik to Deploy AI-Driven SOMA Pro System Across 85MW of New Italian Solar Tracker Projects - ForexTV
Solargik AgriPV Installation Solargik AgriPV Installation Solargik signs 85MW of new solar tracker deployments in Italy.Partnerships with Revalue and Free Ingegneria bring solar power to areas where conventional solutions cannot operate.Solargik unlocks the potential of sustainable solar power in complex agricultural areas.Solargik’s total Italian pipeline now reaches hundreds of MW, helping accelerate the country’s energy transition. Jerusalem and Milan, July 11, 2025 (8:30 AM CET) – Solargik, a global pioneer in photovoltaic terrain-adaptive energy solutions today announced the signing of 85 megawatts (MW) in new utility-scale solar projects across Italy, marking a significant step in opening up solar deployment in areas long considered too steep, constrained, or regulated for viable installation in Europe. The contracts - spanning a 45MW portfolio with Revalue, a third agreement with Free Ingegneria, and an additional 20MW challenging AgriPV project in Southern Italy - add to Solargik’s already substantial pipeline in Italy, bringing total signed capacity to hundreds of megawatts, further positioning the company as a key player in driving Italy’s clean energy transition. From the northeast to the southern regions of Basilicata, the projects reflect a growing shift in the Italian landscape: solar energy reaching areas previously written off as unbuildable or off-limits. Solargik unlocks solar growth as land constraints rise in Italy In 2024, Italy’s solar energy market saw record growth, adding about 6.8 GW of new solar capacity - a 30% increase over the previous year. As demand soars, competition for suitable land is intensifying, particularly with new national guidelines limiting the use of prime farmland for solar farms. Solargik’s terrain-adaptive and AgriPV-compatible tracker systems offer a timely solution helping Italy expand clean energy capacity even where land is limited. “Italy is one of the most strategically important markets for Solargik,” said Gil Kroyzer, CEO of Solargik. “What makes these projects exciting is not just the scale, but the innovation involved - sloped terrain, AgriPV readiness, low-impact deployment. They showcase how our smart systems unlock solar potential in all terrains, including places others would avoid. We’re proud to partner with forward-thinking developers like Revalue, Free Ingegneria, and others, each bringing a unique and ambitious vision that we help turn into reality. These are the kinds of solutions needed to accelerate the energy transition.” Revalue: Scaling solar impact through fast-track deployment Solargik’s collaboration with Revalue, 45MW across ten different project sites, is planned for fast-track delivery by the second half of 2025, leveraging Solargik’s low-impact tracking systems to minimize grading and maximize yield across diverse terrain. “Solargik brings a rare combination of technical depth and practical execution,” said Luca Di Giacomo, co-CEO of Revalue. “They’ve helped us deploy quickly across multiple sites while meeting both performance and permitting goals.” Solargik delivers engineering solution for steep-slope solar sites in 20MW Free Ingegneria portfolio Solargik’s contract with Free Ingegneria covers a 20MW portfolio of four ground-mounted solar projects in Italy, all scheduled for completion by 2026. The sites include slopes as steep as 40% - terrain that typically makes solar deployment technically and economically unfeasible.Solargik’s solution overcame this barrier by adjusting tracker orientation and deploying short-structure systems engineered for steep and uneven land. This approach allowed the projects to move forward within tight environmental and permitting constraints, without compromising on cost or performance. “Solargik’s adaptive engineering gave us options where none seemed possible,” said Marco Giovannini, CEO of Free Ingegneria. “Their ability to rethink standard layouts was essential in overcoming the site’s challenges.” AgriPV projects: advancing solar on farmland in Basilicata The additional project within Solargik’s 85MW Italian rollout includes an AgriPV development for 20MW in the southern region of Basilicata. The project is situated on sloped agricultural land and includes strict environmental and permitting constraints. Solargik is deploying a specialized tracker system designed for AgriPV environments with 1.3 m ground clearance and a maximum height of 2.5 m. Solargik solutions are designed for low-impact development, avoiding cutting into the terrain, aligning with sustainable permitting policies, and offering a path forward for agricultural zones where conventional systems would be ruled out. About Solargik Solargik is a global leader in photovoltaic tracking and energy management, specializing in intelligent, terrain-adaptive solar systems that deliver strong performance in complex and constrained environments. Its lightweight, single-axis trackers are engineered for maximum efficiency on slopes up to 30% and in agrivoltaic applications. Powered by the proprietary SOMA Pro SCADA platform, Solargik provides integrated control, real-time diagnostics, predictive automation, and performance optimization. Field-proven across more than 300 projects globally, Solargik helps operators maximize output, reduce costs, and unlock the full potential of every site. Founded by solar industry veterans, Solargik is committed to advancing smarter, more adaptable solutions for the future of renewable energy. www.solargik.com HEAD OFFICES48 Emek Refaim St.Jerusalem 9314205Israel MEDIA RELATIONS — GLOBALEliav RodmanSolargikeliavr@solargik.com MEDIA RELATIONS — EUROPEGiovanni Ca’ ZorziCohesion Bureaugiovanni.cazorzi@cohesionbureau.com+33 7 84 67 07 27 Attachments 20250711_Italy expansion_Solargik_FINAL_EN Solargik AgriPV Installation